Lakefront Biotherapeutics (LKFT) EBIT Margin (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of EBIT Margin data on file, last reported at 982.92% in Q1 2026.

• EBIT Margin for Q1 2026 came in at 982.92%, down 77124.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 36.78% (up 10862.0% YoY), and the FY2025 annual result was 26.53%, up 9485.0% from the prior year.
• EBIT Margin eased to 982.92% in Q1 2026 per LKFT's latest filing, from 84.06% in the prior quarter.
• Over five years, EBIT Margin peaked at 240.73% in Q2 2025 and troughed at 982.92% in Q1 2026.
• A 5-year average of 123.64% and a median of 23.74% in 2023 frame the typical range for EBIT Margin.
• The sharpest annual moves came in 2025 and 2026: EBIT Margin surged 64439 bps in 2025, then plunged 77124 bps in 2026.
• A 5-year view of EBIT Margin shows it stood at 2.37% in 2022, then surged by 1787 bps to 39.96% in 2023, then jumped by 376 bps to 190.13% in 2024, then slumped by 56 bps to 84.06% in 2025, then plunged by 1269 bps to 982.92% in 2026.
• Business Quant data shows LKFT's EBIT Margin at 982.92% in Q1 2026, 84.06% in Q4 2025, and 647.3% in Q3 2025.